ArticleJCO precision oncology2025

Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.

Thomas J George et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.